top of page

PHARMACOGENETICS TESTING FOR MEDICATION SENSITIVITY

DNA affects how a patient responds to medications

Personalized medicine is the future of healthcare. It allows patients and practitioners to better understand the precise role genetics play in the prevention and treatment of medical conditions. Pharmacogenetics (PGx) -- the science of how DNA influences an individual’s response to medications – allows a provider to choose the best possible medication for their patient’s condition, removing trial and error from prescribing, improving health outcomes, and potentially reducing healthcare costs.

BIOTAP Beacon™ analyzes 17 genes associated with the safety and effectiveness of 300 common medications used to treat conditions in behavioral health (such as depression, anxiety, etc), pain management, cardiovascular health (like high blood pressure, high cholesterol, etc) and primary care. BIOTAP Beacon™ provides actionable results to practitioners by identifying drug-gene / drug-drug interaction risks for an individual.

BIOTAP BEACON IS A MEDICATION SENSITIVITY PANEL

WHICH INCLUDES THE FOLLOWING GENES:

CYP2D6

CYP1A2

VKORC1

MTHFR

CYP2C9

CYP3A4/3A5

SLCO1B1

COMT

CYP2C19

SLC6A4

Factor II

ADRA2A

CYP2B6

OPRM1

Factor V (Leiden)

HTR2A

What makes BIOTAP Beacon different than other pharmacogenetics tests?

BIOTAP Beacon™ provides a comprehensive, programmatic approach to pharmacogenetics, a true personalized medicine program, which includes:

PATIENT SELECTION CRITERIA

To help identify whether a patient is a good candidate for testing

BIOTAP’s high complexity lab analyzes only those genes where an established correlation to a clinical endpoint or outcome exists. Choosing BIOTAP Medical for laboratory testing means work-ing with top scientists in clinical laboratory medicine who have developed and continuously update BIOTAP Beacon™ through researching the guidelines, literature, and science requisite for interpreting PGx results.

Beacon - A Complete PM Program Slide.png

BIOTAP also works with healthcare systems, payers and employers to identify patient populations at genetic risk for drug-gene interactions (DGI) and drug-drug interactions (DDI).

 

Implementing a pharmacogenetics program with clear treatment goals and outcome analytics tracking may:

1.

Decrease polypharmacy and pharmaceutical costs

2.

Decrease adverse drug reactions (ADRs) and their downstream sequela, thus reducing health costs 

3.

Improve health outcomes

4.

Result in increased workforce wellness and productivity for employer groups

We value MASTERY – We hold ourselves to the highest standards of accuracy and accountability with BIOTAP's carefully curated scientific results

FAST
BIOTAP will have test results available in just 5-7 days
PLANNING
Report provides guidance for future drug considerations
CERTIFIED
Lab is CLIA-Certified and clinical consultations with providers available 
ONE TIME
Testing is only done once in a lifetime

BIOTAP stays up to date on the latest advancements in pharmacogenetics testing, technology, and applications. Our expert team of clinical scientists ensure the most comprehensive and accurate testing available. Our focused goal is to support healthcare providers and employers in improving the lives of the patients they serve.

 

Contact us today about BIOTAP Beacon™.

CONTACT

US

Tel. (502) 566-3588

Fax. (502) 561-0089

info@biotapmedical.com

716 W Main St., Suite 100A

Louisville, KY 40202

bottom of page